Clinical trial NCT06203444: An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
Official title: An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lactation
Lead sponsor: Ardelyx
Sponsor class: INDUSTRY
First posted: 2024-01-12
Enrollment: 7
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: An open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects
Primary purpose: TREATMENT

Brief summary: This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.

Detailed description: This will be an open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects. Potential subjects will be screened to assess their eligibility to enter the study within 15 days prior to the first dose administration. Subjects will receive tenapanor from Days 1 to 4 and will be monitored for 24 hours after the last dose of tenapanor. On Day 4, breast milk to evaluate concentrations of tenapanor and AZ13792925 will be collected pre-dose (Hour 0), 1, 2, 4, 6, 8, and 24 hours post-dose. Subjects will return for a Follow-up visit, 5 to 7 days (Day 10±1) after the last dose. All breast milk not used for PK analyses will be discarded (not fed to infant) starting on Day 1 after the first dose of tenapanor is administered until Day 7 (72 hours after last dose of tenapanor).

Eligibility criteria: Inclusion Criteria:

* Subjects must satisfy all of the following criteria at the Screening visit unless otherwise stated:

  1. Females greater than or equal to 18 years of age.
  2. Body mass index between 18.0 and 35.0 kg/m2, inclusive.
  3. In good health with no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory as determined by the Investigator.
  4. Females must be non-pregnant.
  5. Has been breastfeeding or actively pumping for at least 4 weeks.
  6. Willing to continue regular pumping in order to maintain milk supply for the duration of the study.
  7. Will not feed infant breast milk while taking tenapanor and for 72 hours post the last dose of tenapanor.
  8. Weaning must not be underway, to ensure an adequate milk supply.
  9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

1. Significant medical or psychiatric disorder, as determined by the Investigator that would interfere with participation.
2. Use or intend to use any prescription or non-prescription medications 4 days before first dose of tenapanor until Day 6 of the study, unless deemed acceptable by the Investigator and/or Sponsor.
3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
4. Has mastitis or other condition that would prevent the collection of milk from one or both breasts.
5. Loose stools (Type 6 or 7 on the Bristol Stool Form Scale) ≥2 days in the past 7 days
6. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or 5 half-lives prior to dosing.
7. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study

Primary outcomes:
measure: Concentration of tenapanor and its major metabolite in breast milk
timeFrame: 26 Days
Secondary outcomes:
measure: The safety of tenapanor in lactating females
timeFrame: 26 Days
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: DDSI
state: Oklahoma
city: Madison
country: United States
facility: Fortrea Clinical Research Unit
state: Wisconsin
Study officials:
affiliation: Ardelyx
name: Susan Edelstein, PhD
role: STUDY_DIRECTOR
References: